Sponsor

BrightGene Bio-Medical Technology Co., Ltd.

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name BrightGene Bio-Medical Technology Co., Ltd. appears in 16 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials16
Recruiting shown10
Roles1
SourceClinicalTrials.gov
Advertisement

Clinical trials

16 shown
A Study of BGM0504 in Early T2DM With ObesityNCT07743983 · lead sponsor · 2026-08-30
RECRUITING
Bioequivalence Study of BGM0504 InjectionNCT07382908 · lead sponsor · 2025-12-23
RECRUITING
A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese ParticipantsNCT07294235 · lead sponsor · 2025-12-05
RECRUITING
A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese SubjectsNCT07239973 · lead sponsor · 2025-10-21
RECRUITING
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and WomenNCT07224399 · lead sponsor · 2025-10-09
RECRUITING
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult SubjectsNCT07166081 · lead sponsor · 2025-08-11
RECRUITING
A Study of BGM0504 in Participants With Type 2 Diabetes in IndonesiaNCT07064486 · lead sponsor · 2025-07-04
RECRUITING
A Study of BGM0504 in Participants With ObesityNCT06911203 · lead sponsor · 2025-04-03
RECRUITING
A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and ExerciseNCT06716203 · lead sponsor · 2024-12-02
RECRUITING
A Study of BGM0504 in Participants with Type 2 DiabetesNCT06716216 · lead sponsor · 2024-11-29
RECRUITING
A Study to Evaluate Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without DiabetesNCT07658560 · lead sponsor · 2026-06-30
NOT_YET_RECRUITING
A Study of BGM0504 in Healthy Participants and Participants With Impaired Renal FunctionNCT06929156 · lead sponsor · 2025-05-06
COMPLETED
A Study of BGM0504 in Overweight or Obese ParticipantsNCT06920056 · lead sponsor · 2025-03-24
COMPLETED
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult SubjectsNCT06714955 · lead sponsor · 2024-10-21
COMPLETED
A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese SubjectsNCT06973681 · lead sponsor · 2023-10-13
COMPLETED
A Study of BGM0504 in Chinese Patients With Type 2 DiabetesNCT06974825 · lead sponsor · 2023-08-30
COMPLETED

Drugs studied in this sponsor's trials

4 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing BrightGene Bio-Medical Technology Co., Ltd. as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
semaglutide2
metformin hydrochloride1
tirzepatide1
warfarin1

Sponsor roles

lead sponsor16
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.